Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $17.1667.

KPTI has been the subject of several research reports. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Thursday, June 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors have recently bought and sold shares of KPTI. Context Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the fourth quarter worth $464,000. ADAR1 Capital Management LLC raised its position in shares of Karyopharm Therapeutics by 100.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock worth $368,000 after acquiring an additional 25,000 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth $307,000. Bridgeway Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $163,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth $135,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Stock Up 1.4%

KPTI traded up $0.14 during trading hours on Friday, reaching $10.34. 320,237 shares of the company’s stock traded hands, compared to its average volume of 509,888. Karyopharm Therapeutics has a 52-week low of $3.65 and a 52-week high of $10.99. The firm has a market capitalization of $234.34 million, a PE ratio of -0.69 and a beta of 0.80. The firm has a 50-day moving average price of $9.09 and a 200 day moving average price of $8.17.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million during the quarter, compared to analysts’ expectations of $31.40 million. Equities analysts predict that Karyopharm Therapeutics will post -3.24 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.